Hematoporphyrin derivatives and process of preparing

Details Hematoporphyrin derivatives and process of preparing Hematoporphyrin derivatives and process of preparing

1986-07-24

1989-09-12

Raymond, Richard L.

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C07D48722

Patent

active

048661686

ABSTRACT:
To obtain tumor-selective, photosensitizing drugs useful in the localization of neoplastic tissue and treatment of abnormal neoplastic tissue such as tumors, one of two methods is used. In the first method, a hydrolyzed mixture of the products of reaction of hematoporphyrin with acetic acid and sulfuric acid is cycled through a microporous membrane system to exclude low molecular weight products. In the second method, drugs are synthesized or derived from other pyrrole compounds. The drugs: (1) include two covalently bound groups, each with four rings, some of which are pyrroles such as phlorins, porphyrins, chlorins, substituted pyrroles, substituted chlorins or substituted phlorins, each group being arranged in a ring structure, connected covalently to another group and have a triplet energy state above 37.5 kilocalories per mole; (2) are soluble in water, forming an aggregate of over 10,000 molecular weight in water and have an affinity for each other compared to serum protein such that 10 to 100 percent remain self aggregated in serum protein; and (3) are lipophyllic and able to disaggregate and attach to cell plasma, nuclear membrane, mitochondria, lysosomes and tissue. The drug obtained by the first method has an empirical formula of approximately C.sub.68 H.sub.70 N.sub.8 O.sub.11 or C.sub.68 H.sub.66 N.sub.8 O.sub.11 Na.sub.4. Neoplastic tissue retains the drug after it has cleared normal tissues and illumination results in necrosis. Moreover, other photosensitizing materials may be combined with a carrier that enters undesirable tissues and cells of the reticular endothelial system such as macrophages. These photosensitizing materials: (1) must have a triplet energy state above 3.5 kilocalories per mole; (2) cannot be easily oxidized; and (3) not physically quench any required energy state. Preferably, this photosensitizing material should be lipophlic.

REFERENCES:
patent: 3920692 (1975-11-01), Wiersdorff
patent: 4604241 (1986-08-01), Sakata et al.
patent: 4614723 (1986-09-01), Schmidt et al.
patent: 4634557 (1987-01-01), Sato
patent: 4656186 (1987-04-01), Bommer et al.
patent: 4658023 (1987-04-01), Shudo
patent: 4675338 (1987-06-01), Bommer et al.
Lipson et al, J. Nat. Cancer Inst., vol. 26 (1961), pp. 1-8.
Dougherty et al, J. Nat. Cancer Inst., vol. 62 (1979), pp. 231-237.
Dougherty et al, Cancer Res., vol. 38 (1978), pp. 2628-2635.

Affiliated with

Also associated with

Rating

Hematoporphyrin derivatives and process of preparing does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hematoporphyrin derivatives and process of preparing, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hematoporphyrin derivatives and process of preparing will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-917684